-
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
•
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd., (SHE: 000963) regarding their joint development of the type 2 diabetes drug TTP273. Huadong, confirming the cancellation, stated that TTP273 was found to be inferior to its own drug candidate, HDM1002. TTP273, a first-in-class, non-peptide,…
-
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
•
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based Huadong Medicine Co., Ltd (SHE: 000963) regarding their collaboration on the type 2 diabetes drug TTP273. Huadong confirmed the news, stating that TTP273 was considered inferior to its in-house developed drug HDM1002. TTP273, a first-in-class…
